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Abstract 
Background: The non-melanoma skin cancer is one of the most 
prevalent type of skin cancers, which at least involves 2-3 million 
people annually. In recent decades, we have witnessed a considerable 
rise in the incidence of NMSC in Iran. In this paper, we studied the 
expression of the new lncRNA colon cancer-associated transcript 2 
(CCAT2) in cases of non-melanoma skin cancer (NMSC). 
Methods: The sample included 36 patients and 30 healthy subjects, of 
whom, we extracted the total RNA from tissues. Using the cDNA 
synthase, we conducted the real time PCR. Using the SPSS software, 
we analyzed the data and drew the graphs by PRISM software. The 
index of P<0.05 was considered significant. 
Results: The values of CCAT2, TCF7L2 and MYC indicated a 
considerable expression rise in the NMSCs in comparison with the 
controls. In addition, the expression of CCAT2 was found  to be higher 
in high-grade tumors than low-grade tumors. According to results, 
there is a relationship between CCAT2 and NMSC initiation as well as 
the progression. The CCAT2 functions by its downstream genes, 
TCF7L2 and MYC, with an impact on the Wnt signaling pathway. 
Conclusions: based on the results, the lncRNA CCAT2 acts as a 
potential biomarker for NMSC pathogenesis. 
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Introduction 
Nearly the most frequent type of cancer throughout the 
world is the skin cancer, which involves higher than 35% of 
cases.1The non-melanoma skin (NMSC) is also the most 
prevalent type of skin cancer occurring minimally in 2-3 
million people per year. The basal-cell cancers account for 
about 80% of the NMSCs, while squamous-cell carcinomas2 
involve the rest 20%. The epidermal keratinocytes3 are the 
origin of non-melanoma skin cancers, including basal cell 
carcinomas (BCCs) and squamous cell carcinomas (SCCs). A 
dramatic rise has occurred in recent decades in the rate of 
NMSCs, which appears to be one of the most common 
malignancies. These malignancies cause major health problems 
(usually death) due to their high frequency of disabilities 
despite their low mortality rates. Studies have identified 
various genetic alterations as the etiology of NMSCs.4 
A growing area of cancer research has focused on the 
noncoding RNA (ncRNA) in the last decade.5,6 Current studies 
are more concentrated on two types of ncRNAs: microRNAs 
and long noncoding RNAs (lncRNAs). Through specifically 
pairing to the 5′UTR of mRNAs, the microRNAs do their 
regulatory function, and thus, mediate subsequent mRNA 
degradation or inhibition of translation.7,8 Based on evidence, 
the lncRNAs play a role in all cellular biology aspects, 
indicating their involvement in more complex molecular 
mechanisms than the microRNAs.9,10The altered expression of 
lncRNAs has been seen in various types of cancer. Also, 
several deregulated lncRNAs are critical for cancer initiation, 
progression, and invasion.11 
Colon cancer-associated transcript 2 (CCAT2) is an 
oncogenic lncRNA, which increases the tumor progression, 
metastasis, and chromosomal instability.12It was first 
discovered and identified as a highly expressed RNA in the 
microsatellite-stable colorectal cancer. The CCAT2 lies within 
the 8q24 genomic region with the role of producing a cancer-
related single nucleotide polymorphism (SNP), 
rs6983276.12According to several genome-wide association 
studies (GWAS), the rs6983276 polymorphism is related to 
intestine cancers13,14 and epithelial cancers.15 Moreover, the 
WNT signaling pathway is activated by CCAT2 via TCF7L2 
essential to the progression of multiple types of cancers.  
As no studied have been done on CCAT2 in the NMSCs so 
far, we decided to assess the expression profile of CCAT2 in 
the NMSCs to distinguish its clinical correlations. 
Materials and Methods  
We gathered the information of 16 BCC cases, 15 
differentiated SCC cases, and 5 undifferentiated SCC cases in 
this cross-sectional study from Cancer Center of Imam 
Khomeini Hospital, Tehran, Iran. The study sample included 
36 cases and 36 controls (normal subjects). we reviewed all 
cases and the diagnosis was made independently for all 
instances. An informed consent form was signed and approved 
by all subjects.  We graded the SCC cases based on Border`s 
criteria, while the basal cell carcinomas were categorized due 
to the Rippey’s classification.  
Employing the GRC’s FFPE kit (Qiagen, Germany) and 
based on the manufacturer’s instructions,16 we extracted the 
total RNA from the tissues. Also, we treated the total RNAs 
with DNase I (Sigma, USA) for 30 min at 37 ºC to eliminate 
any possible genomic DNA contamination. We examined the 
integrity and concentration of extracted RNAs by Agilent RNA 
6000 Nano Kit (Applied Bio Systems, USA). Using 3-5 µg of 
purified total RNA with the RevertAid™ reverse transcriptase 
(Applied Bio systems, USA) in a total 20 µl reaction mixture 
(according to the manufacturer’s instructions), we conducted 
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the reverse transcription reaction for the first strand cDNA 
synthesis. 
We estimated the mRNA expression levels of CCAT2, 
MYC, and TCF7L2 genes using proper primers. The relative 
expression of each gene was assessed compared to the 
housekeeping gene of Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) with specific primers. All primers 
were designed using the PRIMER EXPRESS software 
(Applied Biosystems, USA). Using the specific primers (Table 
1), we made the amplifications. According to the 
manufacturer’s instructions, the quantitative RT-PCR was done 
by the 7500ABI system (Applied Biosystems, Foster, CA, 
USA) in a final reaction using the volumes of 20 µl with 20 
ngcDNA, 10 µl of SYBR Green I master mix (Takara, Shiga, 
Japan), and 200 nM of forward and reverse primers. The PCR 
reaction process was as follows: it started with denaturation of 
templates at 95 ºC for 3 min, which was followed by 40 cycles 
of denaturation at 95 ºC for 15 sec and annealing/extension at 
60 ºC for 30 sec. The PCR products specificity was evaluated 
by running them on a 2% agarose gel to verify their size and 
dissociation curve analyses. A serial diluted cDNA was 
employed to achieve a standard curve and an amplification 
efficiency for each of the primers of gene transcript. The same 
procedure was used for all genes expression analyses with 
proper negative controls with no template controls to exclude 
or detect any possible contamination. 
Table 1. Characteristics of primers of ccat2, tcf7l2 and myc genes used 
for real time pcr. 
Gene 
name Sequence Product size Tm 
MYC F-5-CCTCCTGCCTCGAGAAGGGC-3 R-5-CTCGCTCCCTCTGCCTCTCGC-3 145 60 
TCF7L2 F-ACGAGCACCTCCTGTATCTTC R-CTCGTTCCCAAGGATCCGATC 142 59 
CCAT2 F- TGGATGTTCTGGGTCTTGACC R-GGGAGTCTCTGTTGATACCTC 182 59 
GAPDH F- CCATGAGAAGTATGACAAC R-GAGTCCTTCCACGATACC 123 59 
Using the comparative threshold cycle as described by 
Livak Briefly, we estimated the relative gene expression for 
each gene. Also, the mean threshold cycle (mCT) was obtained 
from triplicate amplification during the exponential phase of 
amplification. We then subtracted the mCT value of the 
reference gene of internal control gene (GAPDH) from mCT 
value of each Tubb3 and TopIIAgenes to achieve ΔCT for each 
gene. The relative expression of each gene was calculated by 
ratio formula (ratio= 2-ΔΔCt)17 following the computation of 
ΔΔCT values of each sample. Three replications were at least 
made for all experiments. 
We analyzed the real time quantitative reverse transcription 
of PCR with T-test using the Graphpad Prism 5.0 program and 
the SPSS software (SPSS, Chicago, IL, USA). A P-value ≤0.05 
was considered significant and the data were indicated as 
mean±standard deviation (SD). 
Results 
The patient’s age was from 47 to 85 years (a mean age of 
68.72). The samples included 15 cases of differentiated SCC, 5 
cases of undifferentiated SCC, and 16 cases of basal cell 
carcinomas (BCC). Based on the Broders` criteria, 5 out of 
SCC cases were grade I, while 11 were grade II and 4 of grade 
III. In BCC cases, 6 were nodular, 6 were Metatypical, and 4 
cases were classified as mixed (Table 2). 
Table 2. Summary of pathological data of the cases 
Differentiated SCC Undifferentiated SCC BCC  
15 5 16 Biopsy 
4 1 - Grade I 
8 3 - GradeII 
3 1 - GradeIII 
- - 6 Nodular 
- - 6 Metatypical 
- - 4 Mixed 
We used the Real Time PCR for cases and controls to 
analyze the expression levels of CCAT2, TCF7L2, and MYC 
genes. According to the Real Time PCR results, a significant 
rise was seen in the CCAT2 rates in the NMSC samples in 
comparison to the normal samples (P<0.05). The expression 
levels of TCF7L2 and MYC also showed a significant increase 
in the NMSCs compared to the controls (Figure 1).  
 
Figure 1. Expression profiles of CCAT2, MYC and TCF7L2 genes in cases and 
controls 
The expression levels of CCAT2, TCF7L2, and MYC 
genes were also assessed between BCC and SCC samples. 
Indicated by the results, a significant increased expression of 
CCAT2 was seen in the SCC samples compared to the BCC 
samples. Moreover, the analysis demonstrated a statistical rise 
in the levels of TCF7L2 and MYC in the SCC samples (Figure 2).  
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Figure 2. Expression profiles of CCAT2, MYC and TCF7L2 genes in SCC and BCC 
samples 
We compared the expression levels in different grades of 
SCC and BCC samples to evaluate the expression of CCAT2 
and its downstream genes (TCF7L2 and MYC in this study). 
The analysis results suggested no significant difference in the 
expression of CCAT2 between grades I and II. The expression 
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of CCAT2 in grade III was however considerably higher than 
the grade I and II samples. As for TCF7L2 and MYC genes, the 
expression level showed a significant rise in the grade III 
compared to grade I tumors (P<0.05). Nevertheless, no 
difference was found in the gene expression of TCF7L2 and 
MYC between grades III and II, and between grades II and I as 
well (P>0.05)(Figure 3). 
 
Figure 3. Expression profiles of CCAT2, MYC and TCF7L2 genes in different 
grades of SCCs 
We also evaluated the expression level of these genes in 
different types of BCC. We observed that the CCAT2 
expression was significantly higher in the nodular type 
compared to the metatypical samples. Compared with mixed 
and metatypical tumor samples, the TCF7L2 expression 
showed increase in the nodular samples (P<0.05). However, no 
significant difference was found in the expression level of 
MYC in the BCC samples (P>0.05). 
Discussion 
CCAT2 is a new LncRNA in the 8q24 genomic region, 
which harbors rs6983267 SNP. Based on reports by previous 
research, CCAT2 can function as an oncogenic gene involved 
in multiple cancers progression.12In this study, we examined 
the expression of CCAT2 and its downstream genes (TCF7L2 
and MYC) in the non-melanoma skin cancer samples. Indicated 
by the results, the levels of CCAT2, TCF7L2, and MYC genes 
expression significantly increased in the skin cancer cases in 
comparison with the controls. This result is consistent with 
previous studies by Redis et al., Ling et al. and Wang et 
al.12,18,19 The human genome is transcribed actively with just a 
small protein-coding genes fraction, while nearly 95 % of the 
transcripts are non-protein-coding genes or ncRNAs, once 
treated as junks.20,21Recent lncRNAs studies have demonstrated 
critical regulatory roles for ncRNAs along with involvement in 
all cancer biology aspects. Various cancer-associated lncRNAs 
have been well described, including MALAT1, HOTAIR, 
HULC, CCAT2, CCAT1, and BCAR4.22-25TheselncRNAs 
prove the human transcriptome complexity, introducing a 
novice paradigm for cancer research. For example, the 
microRNA-mediated cross talk between lncRNAs and mRNAs, 
BceRNA hypothesis has been validated in numerous types of 
cancer.26,27Moreover, GWAS have identified many cancer-
associated SNPs and hot loci, most of which are located in the 
chromosome region of gene desert with no protein-coding 
gene.28,29 
According to Redis et al. research, the CCAT2 is up-
regulated in breast cancer samples, functioning as an oncogene 
with correlation with cancer progression.18Ling et al. also 
demonstrated the regulation of Wnt signaling pathway by 
CCAT2 through TCF7L2 and MYC, which promotes the 
progression and metastasis12 of colon cancer. Based on the 
results, TCF7L2 and MYC indicated increased level of 
expression in the NMSCs, implying that CCAT2 may regulate 
the TCF7L2 and MYC in the skin cancer as well. Another 
outcome was the highly expressed CCAT2 is in the malignant 
skin tumors rather than the low grade tumors, suggesting the 
possible correlation of CCAT2 with increased cancer 
progression and metastasis.  
In conclusion, one can say that the new lncRNA CCAT2 is 
highly expressed in the NMSCs and there is an association 
between CCAT2 expression levels with the skin cancer 
progression. This may indicate that the CCAT2 can be used as 
a potential biomarker for NMSCs. 
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